Table 1 Summary of the published cases to date of patients who have received obinutuzumab
Case | Age and Gender | Months post obinutuzumab | Initial PCR (g/day) | Final PCR (g/day) | Initial creatinine umol/L | Final creatinine umol/L | Initial serum albumin g/L | Final serum albumin g/L | Initial PLA2R titer (RU/mL) | Final PLA2R titer (RU/mL) | IR | Treatments Trialled prior to obinutuzumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 36M | 15 | 17 | 7.56 | 56 | 113 | <15 | 42 | >1500 | <2.1 | Yes | Rituximab 4g total, cyclosporine, prednisolone, cyclophosphamide |
2 | 33M | 12 | 5.17 | 1.43 | 88 | 85 | 22 | 43 | 1235 | <2.1 | Yes | Rituximab 2g total, cyclosporine, prednisolone, cyclophosphamide |
3 | 54F | 18 | 8.6 | 1.1 | 195 | 115 | 33 | 43 | 312 | 5 | No | Rituximab 4g total |
4 | 61M | 9 | 21 | 6.8 | 97 | 124 | 20 | 38 | 100 | <2 | Yes | Rituximab 2g total, cyclosporine, prednisolone, cyclophosphamide |
5 | 54M | 24 | 19.7 | 1.5 | 177 | 150 | 22 | 41 | 170 | <2 | Yes | Rituximab 4g total |
6 | 66M | 6 | 11.3 | *5.9 | 186 | *140 | 17 | *20 | 633 | 5.1 | Yes | Rituximab |
7 | 41M | 24 (PLA2R last tested at 12 months) | 10.73 | *2.2 | 80 | *71 | 27 | *37 | 39 | 1.8 | Yes | Prednisolone, tacrolimus |
8 | 68M | 36 | 7.8 | *0.5 | 115 | *106 | 21 | *38 | 261 | NA | NA | Rituximab |
9 | 76F | 12 | 5.8 | *0.5 | 124 | *106 | 28 | *35 | 79 | 3.2 | Yes | Prednisolone, tacrolimus |
10 | 67M | 6 (died at 6 months) | 8.49 | *3.2 | 133 | *97 | 28 | *32 | 57 | 7.6 | Yes | Rituximab, prednisolone, tacrolimus, mycophenolate |
11 | 50M | 6 | 4.6 | *1.2 | 133 | *133 | 36 | *38 | NA | NA | NA | Prednisolone, tacrolimus, mycophenolate |